Dupilumab vs placebo was linked to improved health-related quality of life and respiratory symptoms in patients with COPD and T2 inflammation.
The Global Initiative for Chronic Obstructive Lung Disease, or GOLD, COPD exacerbation history groups were “mediocre” in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback